





PHARMACEUTICAL 2023

Elicio Therapeutics Inc.
Rank 187 of 446



The relative strengths and weaknesses of Elicio Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Elicio Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Elicio Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 75% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	51,430
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,369
Liabilities, Non-Current	2,481
Other Assets	1,087
Other Compr. Net Income	189
Other Expenses	9,185
Other Liabilities	168
Other Net Income	814
Other Revenues	2,301
Property and Equipment	273
Research and Development	18,100
Selling, General and Administrative Expense	14,637

Output Variable	Value in 1000 USD
Assets	52,790
Liabilities	9,018
Expenses	41,922
Revenues	2,301
Stockholders Equity	43,772
Net Income	-38,807
Comprehensive Net Income	-38,712
Economic Capital Ratio	118%